Latest News and Press Releases

NurExone Expands European Engagement with Investor Events in Germany and Switzerland

NurExone's Exosome-Based ExoPTEN Targets Three High-Value Nerve Injury Indications

TORONTO and HAIFA, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to provide a business update and...

ExoPTEN’s Preclinical Study Demonstrates Significant for Enhancing Motor Function, Increasing Blood Flow, and Faster Recovery After Spinal Cord Injuries

TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be...

FYR announced the appointment of industry veteran Chris Howlett to its Independent Board of Directors.

NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update

European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry

NurExone’s Groundbreaking Exosome Therapies to be Showcased at Fall U.S. Conferences